Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
dc.contributor.author | Ledermann, JA | |
dc.contributor.author | Oza, AM | |
dc.contributor.author | Lorusso, D | |
dc.contributor.author | Aghajanian, C | |
dc.contributor.author | Oaknin, A | |
dc.contributor.author | Dean, A | |
dc.contributor.author | Colombo, N | |
dc.contributor.author | Weberpals, JI | |
dc.contributor.author | Clamp, Andrew R | |
dc.contributor.author | Scambia, G | |
dc.contributor.author | Leary, A | |
dc.contributor.author | Holloway, RW | |
dc.contributor.author | Gancedo, MA | |
dc.contributor.author | Fong, PC | |
dc.contributor.author | Goh, JC | |
dc.contributor.author | O'Malley, DM | |
dc.contributor.author | Armstrong, DK | |
dc.contributor.author | Banerjee, S | |
dc.contributor.author | Garcia-Donas, J | |
dc.contributor.author | Swisher, EM | |
dc.contributor.author | Cameron, T | |
dc.contributor.author | Maloney, L | |
dc.contributor.author | Goble, S | |
dc.contributor.author | Coleman, RL | |
dc.date.accessioned | 2020-06-15T12:57:41Z | |
dc.date.available | 2020-06-15T12:57:41Z | |
dc.date.issued | 2020 | en |
dc.identifier.citation | Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(5):710-22. | en |
dc.identifier.pmid | 32359490 | en |
dc.identifier.doi | 10.1016/s1470-2045(20)30061-9 | en |
dc.identifier.uri | http://hdl.handle.net/10541/622981 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/ 10.1016/s1470-2045(20)30061-9 | en |
dc.title | Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial | en |
dc.type | Article | en |
dc.contributor.department | Department of Oncology, UCL Cancer Institute, University College London and UCL Hospitals, London, UK. | en |
dc.identifier.journal | Lancet Oncology | en |
dc.description.note | en] |